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https://doi.org/10.1016/j.jaci.2018.01.045A type III complement factor D
deficiency: Structural insights for
inhibition of the alternative pathwayTo the Editor:
We investigated an alternative complement pathway (AP)
deficiency in a patient with absent alternative pathway hemolytic
activity but normal classical pathway hemolytic activity
recovering from invasive meningococcal infection (for patient
and sibling details, see Patient details in this article’s Online
Repository at www.jacionline.org). Serum reconstitution with
proximal AP components suggested a factor D (FD) deficiency
(Fig 1, A). Sanger sequencing of CFD identified a rare
homozygous missense mutation (c.602G>C) in exon 4 in the
patient (II-1) and sibling (II-2), resulting in an arginine to proline
substitution (p. R176P) (see Fig E1, A, and reference E9 in this
article’s Online Repository at www.jacionline.org). This
genotype cosegregated with an alternative pathway hemolytic
activity–null phenotype, as the parents, both heterozygotes, had
normal alternative pathway hemolytic activity (Fig 1, B). In
contrast to previously confirmed FD deficiencies,1-3 all members
of the pedigree had normal levels of circulating FD, as
corroborated by Western blot (see Fig E1, B). Meanwhile,
identical circular dichroism spectra and melting curves of
recombinant wild-type (WT) and R176P FD precluded gross
changes in FD structure or stability, suggesting a functional
deficiency (Fig 1,C, and see Fig E1,C). We assessed the cleavage
of C3b-bound factor B (FB) by recombinant WT and mutant FD
(R176P, R176A, R176Q). WT FD could cleave C3b-bound FB to
produce fragments Bb and Ba. Conversely, R176P FD
demonstrated diminished in vitro catalytic activity at all
concentrations and had negligible activity at physiological
concentration (0.04 mmol/L) (Fig 1, D, and see Fig E1, D).
Reconstitution of FD-depleted serum with R176P FD also
demonstrated impaired AP-mediated hemolysis (see Fig E1, E).
FD’s serine protease activity depends on obligatory binding to
the C3bB complex via 4 exosite loops (residues 132-135,
155-159, 173-176, 203-209). This leads to rearrangement of the
self-inhibitory loop (199-202), allowing realignment of His41
and Asp89 with Ser183 to form the active catalytic triad (see Fig
E2,A andB, in this article’s Online Repository at www.jacionline.
org).4,5 Mutation R176P lies outside the active site, within one of
the FB-binding exosite loops.We used molecular dynamics (MD)
stimulations to study how the R176P mutation affects the FD
protein fold (see Fig E2, C). In mutant FD, we observed a
rearrangement of the exosite loop 155-161within 50 nanoseconds
of simulation (Fig 2, A). This was unexpected because loop
155-161 was not in direct contact with residue 176. Average
structures generated from the final 50 nanoseconds of simulation
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FIG 1. Assessing the contribution of mutation R176P to AP dysfunction. A, Alternative pathway hemolytic
activity (AP50) assay assessing patient serum supplemented with properdin (P), FB, or FD. B, The immediate
family pedigree of the patient with the CFD genotype, serum AP50, and serum FD concentrations displayed.
D represents the WT allele and d, the mutant allele (c.602G>C). C, Thermal shift assay of WT and R176P FD.
D, Serial dilutions of recombinant WT or R176P FD were incubated with C3b and FB. The SDS-PAGE gel,
stained with AcquaStain, shows the individual proteins and resultant products.
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FIG 2. Defining the effects of the R176P mutation on FD function. A and B, FB-binding exosite loop 155-167
assumes a new conformation in mutant FD simulation. Arrows highlight average Ca position shifts of 2
residues that bind C3bB in the R176P FD simulation. C, Loss of shape complementarity at the FD-C3bB
interface. FD exosite loops from published cocrystal structures (white, Protein Data Bank ID: 2XWB) overlaid
with the simulated loops of WT and mutant FD. D, Distance sampled between the active site Nε2 nitrogen of
His41 and Og of Ser183 during each simulation. The shorter distance is necessary for catalytic activity. E and
F, Surface plasmon resonance binding measurement of enzymatically inactive recombinant FD (R176P/
S183A or WT/S183A) to C3bB complex. G, Steady state kinetics for Z-Lys-SBzl cleavage by WT, R176P,
R176A, and catalytically inactive control S183A FD. RMSD, Root-mean-square deviation.
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key FB-binding residues Asp161 and Arg157 were shifted by
4.3 A and 1.9 A, respectively (Ca average position) (Fig 2, B).
Superimposing these MD average structures onto the crystal
structure of the C3bB-D complex revealed that Asp161 and
Arg157 assumed a conformation that no longer supported binding
due to loss of shape and charge complementarity to the FB surface
(Fig 2, C). The other 3 exosite loops retained their
binding-competent conformations. After assuming the new
conformation, exosite loop 155-161 demonstrated higher
conformational mobility (root mean square fluctuation) relative
to WT (Fig E2, D and E). In contrast, the mobility of loops
containing catalytic residues His41 and Asp89 decreased in the
mutants. Using the distance between His41 and Ser183 during
MD simulations as a proxy for the active site conformation, we
observed that WT could sample the short distance necessary for
a catalytically active conformation (Fig 2, D). Conversely, in
both mutant simulations, the distance remained larger, consistent
with His41 pointing away from the active site. Therefore, inaddition to disruption of key FB-binding residues, mutations
R176P and R176A appear to stabilize the self-inhibited
conformation of free FD.
To assess the binding of FD to C3bB, we used surface plasmon
resonance. Coinjection of catalytically inactive FD (WT/S183A)
with FB demonstrated a dose-dependent increase in binding to
C3b and complex formation (Fig 2, E). In contrast, R176P/S183A
FD lacked any detectable binding (Fig 2, F). Consistent with the
stochastic transitions of free WT FD to the active conformation
observed in the MD simulation, FD has a low level of esterolytic
activity toward a small synthetic substrate, Z-Lys-SBzl (Fig 2,D).
Surprisingly, R176P FD demonstrated a loss of esterolytic
activity similar to the active site mutant, S183A (see Fig 2, G).
Deficiency of properdin, the most common AP deficiency, can
result from absent (type I), low (type II), or normal
but nonfunctioning (type III) protein levels (for reference,
see reference E10 in this article’s Online Repository
at www.jacionline.org). Meanwhile, previously confirmed
deficiencies of activating complement serine proteases have all
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unique deficiency: R176P FD is fully expressed and stable, but
enzymatically inert, constituting a functional or type III
deficiency. Recent preclinical evidence6 that FD-deficient mice
are susceptible to diabetes prompted metabolic assessment in
the FD-deficient patients. No abnormality was detected (for
details, see Functional FD deficiency does not result in impaired
oral glucose tolerance section, Fig E3, and Table E1 in this
article’s Online Repository at www.jacionline.org).
Overactivation of AP is implicated in numerous inflammatory
disorders, including age-relatedmacular degeneration. Therefore,
blockade of the AP by targeting the rate-limiting enzyme, FD, is
an attractive approach to controlling disease progression. An
anti-FD Fab fragment targeting the 2 distal exosite loops has
shown some benefit in phase II clinical trials for treatment of dry
age-related macular degeneration.7 In vitro studies indicate that it
inhibits binding to the C3bB complex but increases esterolytic
activity toward small-molecule substrates.8 This may result in
unwanted clinical effects due to nonspecific activity or limit its
efficacy in vivo. In the case of R176P FD, both FB-binding and
esterolytic activity are abrogated through exosite hindrance and
stabilization of the self-inhibited state. Loop 173-176 is thus a
promising target for allosteric inhibitors of FD that stabilize the
inhibitory loop in addition to binding-blockade. A structure-
based design approach to targeting FD has recently succeeded
in identifying candidate FD inhibitors where high-throughput
screens had failed,9 highlighting the benefits of integrating
structural information into candidate drug screens. Comprehen-
sive definition of the structural and molecular determinants of
in vivo FD activity is critical for this. This study of the R176P
mutation demonstrates how in-depth mechanistic analysis of
rare complement deficiencies can deliver such insight validated
clinically by in vivo human evidence of AP blockade.
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https://doi.org/10.1016/j.jaci.2018.01.048Nasal epithelium as a proxy for bron-
chial epithelium for smoking-induced
gene expression and expression
Quantitative Trait LociTo the Editor:
The criterion standard in respiratory research is the investigation
of biosamples of the lower airway, which are usually obtained by
bronchoscopy. However, this is an invasive procedure, with a
substantial burden to patients that is also associatedwith high costs.
Recent studies have suggested that nasal brushings may
provide a less invasive source of airway epithelial cells that
PATIENT DETAILS
A 19-year-old, South Asian female presented with a 24-hour
history of high fever, rigors, delirium, and diarrhea. On clinical
examination, she was febrile with a purpuric rash and a reduced
level of consciousness (Glasgow Coma scale score: 9 of 15).
Intravenous antibiotic therapy was initiated for provisionally
diagnosed meningococcal septicemia. She was intubated and
transferred to the intensive care unit where she developed
disseminated intravascular coagulation, for which she received
treatment. Results from blood cultures drawn at the time of
admission confirmed an infection with Neisseria meningitides
serogroup Y. Her clinical condition improved with intensive
care support and antimicrobial therapy. She was discharged after
2 weeks with minimal sequelae including bilateral leg scarring,
a sacral pressure sore, and mild bilateral hearing loss.
At the age of 5 years, she had received bilateral tympanostomy
tubes for recurrent ear infections and otitis media with effusion
but had no other unusual infections as a child. She received the
full course of childhood vaccinations as per the national
immunization schedule.
On screening for immunodeficiency, laboratory measurement
demonstrated a normal full blood count with normal counts of
lymphoid cells. The titers of C3, C4, mannose-binding lectin and
C1q were within normal range, but there was undetectable AP50
in conjunction with normal classical pathway hemolytic activity.
In view of her complement deficiency, shewas prescribed lifelong
phenoxymethylpenicillin as antimicrobial prophylaxis. She was
also vaccinated for meningitis serogroups A, C, W-135, and Y;
meningitis C; pneumococcus; and Haemophilus influenza B to
which she developed high antibody titer responses.
Her sole sibling, a younger male, who was homozygous
for the same mutation, leading to an identical pattern on
immunodeficiency screening, was healthy at assessment. He
reported no excess of infections in the past. Of note, he reported
having been treated empirically for suspected meningitis, at age
11 years, while travelling in Mauritius from which he recovered
with no sequelae after a standard course of antibiotics.
FUNCTIONAL FD DEFICIENCY DOES NOT RESULT
IN IMPAIRED ORAL GLUCOSE TOLERANCE
Recent preclinical evidenceE1 that FD regulates insulin
secretion prompted metabolic assessment of the patient and
her sibling. They had a body mass index of 19.3 kg/m2 and
23.1 kg/m2, respectively. Fasting venous plasma glucose
(5.2-5.4 mmol/L) and insulin (29-39 pmol/L) levels were normal
in both subjects (Fig E3). Similarly, plasma glucose excursions
were normal in response to an oral glucose (75 g) challenge. At
120 minutes following glucose administration, glucose levels
remained normal (4.0 mmol/L). Furthermore, circulating
concentrations of leptin and adiponectin, adipokines that regulate
insulin sensitivity, were normal, as were fasting lipid profiles in
both subjects. Thus, glucose homeostasis is not impaired in the
context of genetic, and therefore lifelong, FD deficiency.
These results are consistent with the finding that FD knockout
mice developed impaired glucose tolerance only on a long-term
diabetogenic diet. This suggests that FD may contribute little to
glucose homeostasis in the absence of prolonged metabolic stress.
Alternatively, the role of FD in glucose homeostasis could be
independent of binding to C3bB or independent of its
serine protease activity and, by extension, independent of its
downstream effects on the complement cascade. While congenital
deficiency of FD alone may not lead to insulin insufficiency, Lo
et al’sE1 findings warrant observation of oral glucose tolerance in
such FD-deficient patients under extreme metabolic stress and at
older age. Further research will be required to understand the
role of FD in glucose homeostasis and FD-deficient family pedi-
grees offer a useful clinical insight to this question.
METHODS
Informed consent statement
All study participants gave their informed consent as appropriate under
approved protocols from local institutional review boards. The research was
conducted at University College London and the University of Cambridge
under approved protocols (#04/Q0501/119 for affected individuals,
#07/H0720/182 for family members).
AP50 measurement
AP100 RC003.1 Kit (Binding Site, Birmingham, UK) agar-chicken eryth-
rocyte plateswere preparedaccording to themanufacturer’s instructions,withkit
control and calibration solutions added. Then 5-mL aliquots of test serum were
added to individual wells on the plates over ice. The loaded plates were then
stored at 48C for 18 hours to allow radial diffusion of serum components,
followed by incubation at 378C for 90 minutes to develop zones of lysis. The
plates were then digitally scanned at high resolution, and the diameters of zones
of lysis were measured using ImageJ 1.x computer software (National Institutes
of Health, Bethesda, Md). Representative plates were selected for figures. The
diameter of lysis correlateswithAP50and isexpressedout of100%relative tokit
control. Purified human FD, FB, and properdin for reconstitution assays were
purchased from Complement Tech (Tyler, Tex).
Sanger sequencing
Genomic DNAwas isolated from blood samples with QIAamp Kits (Qiagen,
Hilden, Germany). TheCFD gene PCRwas performedwith primers annealing to
intron sequences close to each exon as described previously.E2 Specifically,
regarding the R176P mutation, a 258-bp genomic fragment comprising exon 4
was amplified by PCR with the primers 59-CTGGGGCA
TAGTCAACCAC-39 and 59-TGGGCCCTGTTCCTACTTG-39. The cDNA
numbering for the CFD variant identified is based on transcript Ref Seq
accession no. NM_001928/Ensembl accession no. ENST00000327726.6
(National Center for Biotechnology Information, Bethesda, Md), beginning at
theATGstart codon. Thegenomic coordinates refer to theGRCh37genomebuild.
Western blot analysis
Pooled control and the patient serumwere diluted to 1:40 inTris-buffered saline
and resolved by SDS-PAGEonNuPAGE4% to 12%Bis-Tris Gels, then blotted to
nitrocellulose membranes. FD was detected using goat anti-human FD (AF1824;
R&DSystems,Minneapolis,Minn) anddonkey anti-goat-IgG IRDye680CW(LI-
COR Biosciences, Lincoln, Neb) secondary antibodies. The membranes were
imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Recombinant CFD expression and purification
Lentiviral transfer plasmid, envelope plasmid (pMD2.G; gift from Didier
Trono; AddGene plasmid #12260; Cambridge, Mass) and packaging plasmid
(psPAX2; AddGene; gift from Didier Trono; AddGene plasmid #12259) were
used to transfect HEK293T cells to produce lentiviral particles. The transfer
vector (modified pLenti-CMV-GFP-Puro; gift of Eric Campeau; AddGene
plasmid #17448) included human FD cDNA (WT, R176P, R176A, S183A)
with C-terminus hexahistidine tag upstream of an IRES-Thy1.1 and a
puromycin resistance gene (PuroR). Transfection was carried out using
Lipofectamine 3000 and, after 24 hours, the media containing the lentiviral
particles was used immediately to stably transduce newly plated HEK293T
cells. After puromycin selection, stably transduced 293T cells were incubated
with FreeStyle media (Gibco, Thermo Fisher Scientific, Waltham, Mass)
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supplemented with 6X Glutamax and 2 mmol/L valproic acid. After 7 to
14 days, secreted recombinant CFD was purified from this media using cobalt
immobilized metal affinity chromatography. CFD was eluted in 150 mmol/L
imidazole in PBS and buffer exchanged by centrifugal concentration
(Vivaspin 20; 10,000 Da pore size; Sartorius, G€ottingen, Germany). Purity
of the sample was confirmed on SDS-PAGE and mass spectrometry.
Measuring in vitro catalytic activity of recombinant FD
Purified human C3b and FB were purchased from Complement
Technology. Recombinant WT, R176P, or R176A FD were mixed in varying
concentrations (1.0mmol/L, 0.2mmol/L, 0.04mmol/L)withC3b (1.0mmol/L)
and FB (1.0 mmol/L) in veronal buffer (Lonza, Basel, Switzerland) with
10 mmol/L MgCl2 to a final volume of 20 mL. Reaction tubes were incubated
for 10 minutes at 378C before the addition of sample loading buffer (NuPAGE
LDS Sample Buffer, Thermo Fisher Scientific) to terminate the reaction. The
samples were then heated to 708C for 10 minutes and resolved by SDS-PAGE
on a Novex NuPAGE 4% to 12% Bis-Tris Gel. The gels were developed
overnight with AcquaStain (Bulldog Bio, Portsmouth, NH), washed for
1 hour with distilled water, dried, and digitally scanned at high resolution.
Analysis of percentage cleavage of FB was calculated by densitometry
analysis using ImageJ 1.x computer software. Statistical comparisons between
WT and R176P FD activity were performed at each concentration, from 4
independent experiments using the Kruskall-Wallis nonparametric t test.
Circular dichroism spectroscopy and thermal shift
assay
WT and R176P catalytically inactive (S183A) proteins were purified by size
exclusion chromatography in chloride-free 0.1 mol/L sodium phosphate pH 7.0,
diluted to a concentration of 2 mg/mL (72.4 mmol/L), and loaded into a 0.1-mm
quartz sample cell. Circular dichroism spectra were recorded at 208Con a Jasco J-
810 spectropolarimeter (OklahomaCity,Okla) equippedwith a JascoPTC-348WI
temperature controller. Spectra were acquired from 190 to 260 nm with 0.1-nm
resolution and 1-nm bandwidth. Final spectra are the sum of 20 scans acquired at
50 nm/min. For the thermal shift assay, 2 mg of protein were mixed with SYPRO
Orange (Fisher Scientific UK Ltd, Loughborough, UK) in PBS with 25 mmol/L
HEPES and fluorescence data acquired on a ViiA 7 real-time PCR system with
thermal denaturation over increasing temperatures observed using 18C intervals.
MD simulation of mutant FD
Starting models were derived from crystal structures of S183A FD (Protein
Data Bank [PDB] ID: 2XW9, 1.2 A resolution) reported previously.E3 The
catalytic residue was reverted to serine during the MD setup. CootE4 was
used to place the Pro176 side chain in the Arg176 experimental density while
minimizing clashes with surrounding atoms and aiming to achieve a favorable
initial geometry. The resulting structures were further adjusted in UCSF
Chimera (Resource for Biocomputing, Visualization, and Informatics,
San Francisco, Calif).E5 The GROMACS package (Gromacs, University of
Groningen, Groningen, The Netherlands)E6 was used to set up and run MD
simulations. The AMBER99SB-ILDN force field (Gromacs)E7 and TIP3P
water model were used and the structures placed in dodecahedral boxes
with 10 A padding and surrounded with solvent including water and
150 mmol/L NaCl. Following steepest gradient energy minimization, a
modified Berendsen thermostat (2 groups, time constant 0.1 picoseconds,
temperature 310 K) followed by a Berendsen barostat (isotropic, coupling
constant 0.5 picoseconds, reference pressure 1 bar) were coupled to the system
over 100 picoseconds. One hundred–nanosecond runs of unrestrained MD
trajectories were produced. Following removal of periodic boundary condition
artefacts,MD runswere visualized and analyzed in Chimera and bulk statistics
extracted using GROMACS analysis routines.
Surface plasmon resonance
Binding experiments were carried out based on established protocol using a
Biacore T200 instrument.E8 FB and FDwere buffer exchanged by gel filtration
into veronal buffer with 10mmol/LMgCl2. C3b was immobilized on the CM5
chip by amine coupling to achieve 8000 resonance units. A dual injection
program was designed where 0.1 mmol/L or 1 mmol/L FB was injected at a
flow rate of 30 mL/min for 3 minutes, followed by a second injection of a
mix of 0.1 mmol/L or 1 mmol/L FB and FD at 30 mL/min for 4 minutes. After
5 minutes for dissociation, the chip was regenerated by 3 5-minute washes in
40 mmol/L acetate 1 3 mol/L NaCl (pH 5.5). The chip was reequilibrated in
assay buffer for 5 minutes. Catalytically inactive FD (S183A) or double
mutant R176P/S183A were used to emulate the binding response of WT or
R176P, respectively, while preventing cleavage of FB and subsequent
dissociation of the complex.
Esterolytic activity of FD
Z-Lys-SBzl was purchased from Sigma-Aldrich (St. Louis, Mo) in powder
form and reconstituted to 100 mmol/L in 70% dimethyl sulfoxide. The assay
buffer consisted of 50mmol/LHEPES (pH 7.5), 220mmol/LNaCl and 2mmol/
L of Ellman reagent (5,5-dithio-bis-[2-nitrobenzoic acid]; Sigma-Aldrich). Each
reactionmixture contained FD (80 nmol/L), variable Z-Lys-SBzl concentrations
(0.2-3.2 mmol/L) and 8% vol/vol of dimethyl sulfoxide in a final volume of
200 mL. Solutions were prewarmed to 378C before addition of substrate to
initiate the reaction. Hydrolysis of Z-lys-SBzl wasmeasured using CLARIOstar
FS microplate reader through equimolar formation of chromophore 2-nitro-5-
thiobenzoate at 405 nm every 30 seconds for 90 minutes (ε 5 13,600 mol/
L21cm21). The rate of hydrolysis was determined from linear slopes of the re-
action curves. Reaction velocities, expressed in apparent turnover values were
plotted against substrate concentration.
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FIG E1. Mutation R176P results in a type III FD deficiency. A, Chromatograms for the DNA sequence
adjacent to position c.602 are shown for each member of the pedigree. The identified variant is rare: the
Exome Aggregation Consortium’s ExAC database reports mutation R176P (variant 19:861943 G/C) at an
allele frequency of 1.049 3 1024, with no homozygotes.E9 B, Western blot analysis of FD in serum from
the patient and healthy control. C, Secondary structural compositions of WT and R176P FD were evaluated
using circular dichroism spectroscopy. D, Comparison of in vitro catalytic activity of recombinant WT,
R176P, R176Q, and R176A FD in terms of FB cleavage. ***P < .001; ****P < .0001. E, Recombinant WT
and R176P FD were tested for the ability to reconstitute AP50 when added to FD-depleted serum.
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FIG E2. Mutation R176P stabilizes the self-inhibited state of FD. A, Structure of free FDE3 (PDB ID: 2XW9)
showing the catalytic triad (Ser183-His41-Asp89) in an inactive conformation stabilized by the
self-inhibitory loop 199-202 (red) and an ion bridge between Asp177 and Agr202. The exosite loops are
shown in yellow. B, Structure of C3bB-bound FDE3 (PDB ID: 2XWB) omitting the C3b and FB components.
FD exosite loops retain a conformation similar to that of unbound FD. C,WT, R176P, and R176A structures
were stable over 100 nanoseconds of unrestrained molecular dynamics simulation with explicit solvent.
D, Root mean square fluctuation (RMSF) in WT and mutant FD over the second half of the trajectory.
E, Differences in WT versus R176 RMSF mapped to the FD structured. MD predicted increased mobility in
exosite loops, notably 155-167, and decreased mobility in loops carrying the catalytic His41 and Asp89
residues.
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FIG E3. Assessment of glucose tolerance in patients with functional FD
deficiency. Patient and sibling were given 75 g of oral glucose at 0 minutes
and blood glucose was measured at regular intervals between 0 and
120 minutes. The error bars indicate the range of plasma glucose
concentrations between the patient and sibling.
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TABLE E1. Fasting measurements of metabolic parameters in the
patient and sibling
Analyte Patient Sibling
Leptin (ng/mL) 10.6 11.3
Adiponectin (mg/mL) 9.7 6.5
NEFA (mmol/L) 391 212
Cholesterol (mmol/L) 4.2 4
HDL (mmol/L) 1.53 1.26
LDL (mmol/L) 2.3 2.3
Triglycerides (mmol/L) 0.8 0.9
HbA1c (mmol/mol) 36 35
HbA1c, Glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; NEFA, nonesterified fatty acids.
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